HealthCode Bio key facts
as of Oct 2026- Developer of health assessment and disease diagnostic reagents and microchips, designed for modern biotechnological solutions.
- HealthCode Bio is valued at approximately $417.9M as of Oct 2026 (last reported valuation).
- Notable investors include Wuxi Industry Development Group, Cathy Fortune Corporation, Shanghai Huamin Investment.
- Status: Privately Held (backing).
HealthCode Bio's last reported valuation, May 2022. Nothing priced has surfaced since.
- ·Watch HealthCode Bio: the Monday email on marks, rounds and moves
HealthCode Bio funding rounds
No funding rounds for HealthCode Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs HealthCode Bio
3HealthCode Bio valuation
HealthCode Bio's last reported valuation was $418 million in May 2022. No priced round, secondary trade or fund mark has surfaced since.
HealthCode Bio investors
3 investors are on record for HealthCode Bio, including Wuxi Industry Development Group, Cathy Fortune Corporation and Shanghai Huamin Investment.
About HealthCode Bio
Developer of health assessment and disease diagnostic reagents and microchips, designed for modern biotechnological solutions. The company focuses on the development of human health assessment and disease diagnostic reagents and microchips, offering a macro bioinformatics testing, monitoring, and analysis system based on de novo protein technology, enabling the healthcare industry with biotech production.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 29
- Website
- healthcodon.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.